Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Myofibroma × Tablets × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 5 Neoplasm Metastasis 2 Vomiting 1 Urinary Bladder Neoplasms 1 TP53 Y220C Mutation 1 Solid Tumors 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Osteosarcoma 1 Neuroblastoma 1 Nausea 1 Myofibroma 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Carcinoma 1 Advanced Solid Tumors 1 Adenocarcinoma of Lung 1

Interventions

Tablets 1 LFA102 monoclonal antibody 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03156127 2017-08-10

A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet

Boryung Pharmaceutical Co., Ltd

Phase 1 Withdrawn

Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡